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The ability to successfully replace lost nigral dopaminergic neurons in Parkinson’s disease (PD) has been
clearly shown with fetal ventral mesencephalic transplants, albeit inconsistently. The need to trial this
approach with stem-cell-derived neurons is approaching, but it should only commence when all the key
issues have been adequately resolved.Parkinson’s disease (PD) is a common
neurodegenerative disorder that affects
about 1 in 800 people worldwide and is
currently incurable. It is characterized by a
movement disorder associated with the
loss of the nigral dopaminergic neurons,
and while it is now well described that the
pathology and clinical features extend
outside these domains, it can nevertheless
be successfully treated formany yearswith
dopaminergic drugs. However, over time
these drugs become less effective as the
disease progresses and generate their
own unique side effects such as dyskine-
sias. As such over the last 30 years there
havemanyattempts tobetter deliver dopa-
mine to the parkinsonian brain using cell-
based therapies and many lessons have
been learned from these studies. These
lessons need to be remembered as we
move toward an era of stem-cell-based
therapies and can best be captured and
discussed around four key questions:
1. What is the evidence that dopami-
nergic cell replacement therapies
work in PD?
2. What characteristics should the
stem-cell-derived dopaminergic
neurons possess?
3. What should the ‘‘first in man’’ trial
with such a cell look like?
4. Will such a therapy ultimately be
competitive with the other dopami-
nergic-based treatments already
available for PD?What Is the Evidence that
Dopaminergic Cell Replacement
Therapies Work in PD?
The use of cell-based therapies for PD has
involved a number of different cell types,but to date the only one that has really
stood the test of time is the fetal dopami-
nergic neuroblast derived from the devel-
oping human ventral mesencephalon
(hVM) (reviewed in Barker et al., 2013).
The preclinical work that led up to the
first open label trials in patients began
with the demonstration that allografts of
VM tissue in the unilaterally lesioned
6-OHDA rat model could survive long
term, receive and make synapses with
the host brain, release dopamine, and
restore behavioral deficits such as drug-
induced rotation back to normal.
While this model is not one of PD, it is
one of striatal dopamine loss and thus
can be used to assess the ability of the
graft to restore dopamine levels in the
striatum back to normal. In this regard
only a few hundred fetal nigral dopamine
cells need to survive grafting to the stria-
tum (they are ineffective when grafted
homotopically to the nigra) to completely
reverse drug-induced rotation (Brundin
et al., 1986). This test therefore lacks a
degree of sensitivity because grafts of
several thousand nigral dopaminergic
neurons produce an effect on drug-
induced rotation that is similar to that
seen with transplants containing only a
few hundred such cells. However, when
combined with other behavioral tests that
haveadopaminergicbasis (e.g., contralat-
eral forelimb use and stepping), the results
provideauseful statementon the function-
ality of the grafted cells. Furthermore, this
ability of a fewhundred fetal nigral dopami-
nergic cells to totally reversedrug-induced
rotation in this model is useful because
it gives a gold standard by which to
assess the equivalence of efficacy of other
cell-based treatments (see below).Cell Stem Cell 15,As a result of this work and its consis-
tency of effect between labs, the first pa-
tients received grafts in the late 1980s,
and a number of open-label studies as
well as two double-blind placebo (or
more accurately imitation surgery) trials
followed. These studies showed that
hVM transplants could survive (as shown
on F-dopa PET scanning and at postmor-
tem) and produce long-lasting clinical
benefits in some patients—to the extent
that some could even stop their anti-PD
medication. However, while in some
patients the effects were transformative
and long-lasting (i.e., >10 years), the
clinical response did vary from patient to
patient. In addition, the two double-blind
studies both failed to meet their primary
end point on efficacy with some patients
also developing side effects in the form
of graft-induced dyskinesias (reviewed
in Barker et al., 2013). As a result many
researchers concluded that this cellular
approach was not worth pursuing, espe-
cially because better symptomatic thera-
pies were now available in the clinic, for
example in the form of deep brain stimula-
tion (DBS) (Olanow et al., 2009). However,
this conclusion was hard to sustain in the
face of the reported long-term clinical
improvements seen in some patients
(Kefalopoulou et al., 2014).
It was on this background that a work-
ing group linking all those involved in
these trials met to decide how best to
move the field forward, which has led to
a new fetal hVM study in PD (TRANS-
EURO). This working group initially sought
to critically appraise the data from all of
the published trials as well as the preclin-
ical data in order to decide whether there
was merit in doing a new trial, and if so,November 6, 2014 ª2014 Elsevier Inc. 539
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type, transplant procedure, and trial
design. This discussion has led to a new
trial that will target young PD patients
earlier in their disease course ahead of
them developing significant L-dopa-
induced dyskinesias (LIDs). The patients
to be grafted (n = 20) will be drawn out
of a larger cohort that are being assessed
longitudinally in an identical fashion, so
that the behavior of those grafted can be
compared against a well-matched natural
history control group, with all patients
being blindly assessed by a third party
to remove investigator bias. By so doing
it is hoped that the extent and reproduc-
ibility of the benefits from hVM transplants
can be better ascertained over a 3 year
follow-up period—the time at which the
primary end point is reached.
This trial is seen as laying the founda-
tions for the next generation of stem-
cell-based trials, and while there are
some arguments for waiting for the results
of this trial before proceeding to any
stem-cell-based clinical trials, this seems
unnecessary given the differences be-
tween the cellular composition of the
tissue to be grafted in these two situa-
tions. In particular fetal VM grafts contain
committed dopaminergic neuroblasts
that are in the final stages of cell division
as well as a large number of other con-
taminating cell types that constitute the
developing VM. In contrast stem cell
grafts are more likely to contain a limited
repertoire of dopaminergic precursors
and neurons while also containing cells
with greater proliferative potential. While
this does allow the reliable generation of
large numbers of cells needed for clinical
trials (which is difficult to achievewith fetal
tissue because it is collected through
termination of pregnancies), it brings
with it the possibility that genetic manipu-
lation of the stem cells will be necessary
for safety reasons (e.g., suicide genes).
This in turn will bring with it other regulato-
ry issues and concerns. Finally, stem-cell-
derived products are likely to be subject
to patents and commercialization, which
may engender less collaboration than
that seen of late in the field of fetal cell
grafting for PD. As such clear differences
emerge when approaches with hVM
grafts and those derived from stem cell
sources are compared, a fact that will
need to be remembered as we move
forward.540 Cell Stem Cell 15, November 6, 2014 ª2What Characteristics Should the
Stem-Cell-Derived Dopaminergic
Neurons Possess?
A number of stem cell sources have been
used in animal models of PD, and it is
important to note that several of them do
not work by dopaminergic cell replace-
ment, such as mesenchymal stem cell
(MSC) transplants. Of course whether
such therapies will be of future value in
PD is a moot point, but here I will restrict
my discussion to those stem cells that
are being designed to deliver dopami-
nergic neurons to replace those lost in PD.
For any purported dopaminergic cell
a number of critical criteria need to be
fulfilled before it can be considered for
clinical use (see below). These fall into
two main categories: one relates to
safety, including the proliferation poten-
tial, stability, and microbial sterility of the
cells; and the other relates to the identity
of the dopaminergic cells and whether
they are authentic nigral (A9) neurons.
The in vitro characteristics of the parent
stem cell line should be as follows:
d have a stable karyotype
d be free of microbiological contami-
nants such as mycoplasma
d be a reliable, stable source of cells
over time made in a fully GMP-
compliant way
The differentiated progeny should be as
follows:
d not contain markers of pluripotency
d not proliferate in an uncontrolled
fashion in vitro
d not form large numbers of nonnigral
dopaminergic neurons
d produce dopaminergic-looking
neurons that express markers of
standard dopaminergic neurons:
TH, DAT, etc., and especially
markers of nigral A9 dopaminergic
neurons (e.g. Girk 2)
d express a transcriptional profile that
is in keeping with human nigral
dopaminergic neurons
d neurophysiologically behave like
nigral dopaminergic neurons
d release dopamine
The in vivo characteristics of the parent
stem cell line should be as follows:
d survive long term after grafting with
functional benefits in animal models
of PD014 Elsevier Inc.d have functional benefits with
numbers of cells similar to those
seen with human fetal VM grafts
d have sufficient axonal outgrowth to
innervate the striatum
d not proliferate in an uncontrolled
fashion in vitro
d not migrate extensively throughout
the CNS
d not form large numbers of nonnigral
dopaminergic neurons or dediffer-
entiate
Many of these issues have been dis-
cussed before, but a couple of points
need highlighting.
First is the need to show that the
derived cells are true midbrain nigral
dopaminergic neurons as assessed using
transcriptional, morphological, and elec-
trophysiological profiling. This confir-
mation is necessary because previously
it has been shown with fetal tissue that
functional recovery in animal models of
PD is contingent on A9, rather than A10,
dopaminergic neurons (Grealish et al.,
2010). Thus the cells must also demon-
strate a capacity for functional recovery
when grafted into the 6-OHDA animal
model of PD that is robust and similar to
that seen with fetal VM tissue, especially
in terms of dose effects. In other words,
the derived dopaminergic neurons should
at the very least completely reverse drug-
induced rotation and do so at a dose that
is similar to that seen with VM tissue. This
reversal will rely not only on them being
A9 neurons but also on them having the
capacity to adequately integrate into and
innervate the surrounding striatal tissue.
Second, these cells need to be shown
to have consistent effects across studies,
ideally in different labs. All too often cell-
based therapies have gone to clinic,
based on single or very limited preclinical
studies with little evidence of robust
survival or behavioral recovery. This at
best leads to phase 1 studies that pro-
duce effects that are hard to explain
from a mechanistic perspective. At worst
such trials will cause major side effects
that have the capacity to derail the
whole field, becausemany commentators
confusingly regard all cell therapies as all
being essentially the same.
As to which cells are likely to come to
clinic first for PD, there are two main
candidates: GMP-grade human ESC-
or iPSC-derived dopaminergic neurons.
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possible tumorigenesis with the latter
also presenting problems relating to the
genomic effects and variability of reprog-
ramming. In addition, concerns remain
about the extent to which PD pathology
can be seen within dopaminergic cell
grafts, which has been an issue in some
fetal allogeneic hVM transplants (Brundin
and Kordower 2012). This issue may be
further complicated with patient-derived
autologous iPSC-derived grafts because
they may have a greater intrinsic capacity
to develop a PD-like pathology. Recapitu-
lation of disease phenotypes is less of
an issue with allogeneic iPSC- or human
ESC-derived dopaminergic neurons,
although ESCs carry a number of ethical
concerns that may be less applicable to
iPSC-derived neurons. That having been
said, there is now evidence that cells
that have many of the characteristics of
authentic nigral neurons can be reliably
and reproducibly generated from human
ESC sources (Kriks et al., 2011) without
evidence of cell overgrowth. However,
their capacity to grow axons of sufficient
length to adequately innervate the host
brain is still an issue.
What Should the ‘‘First in Man’’ Trial
with Such a Cell Look Like?
At a time when the preclinical data allows
(and this includes fulfilling the necessary
regulations of GMP), and only then,
should a clinical trial be considered. This
translation is clearly not without risk,
especially given the chronicity of the clin-
ical condition and treatment compared to
the animal models defining the preclinical
behavior of these cells. Nevertheless, this
process requires a balance between se-
lecting patients with least to lose but
also still with something to gain.
In this respect the history of hVM
allografting is informative in two ways.
First, we know that the inclusion of more
advanced patients, who will almost
certainly form part of these first trials with
stem cells, can be done safely. Second,
the new TRANSEURO trial has involved a
process that cannowbeadoptedby those
involved in taking these stem-cell-derived
dopamine cells to the clinic (GFORCE)
(Abbott 2014). This approach will ensure
that the first trials can be done in a collab-
orative way (although there are issues
unique to stem cells that may ultimately
make this difficult to achieve—see above)and minimize the risk of rushing to the
clinic prematurely. In addition, it has to be
realized that these initial trials are unlikely
to be optimal at their first attempt given
the difficulties in translating cell doses
(especially with grafts containing prolifer-
ating stem cells) from animal studies to
patients. Thus the process is likely to be
an iterative one, as was done with hVM
trials in PD and more recently in the
ProSavin gene therapy trial (Palfi et al.,
2014). As such, the first trials will involve
very few patients (n = 2 or 3) with moder-
ately advanced disease who are likely to
receive grafts containing suboptimal
numbers of cells to ensure that there is
no overgrowth of the transplant. Finally,
these new therapies require long term
follow-up and access to postmortem
tissue from these patients. This analysis
is necessary because the maximal bene-
fits of cell-based therapies can take years
to be realized (Kefalopoulou et al., 2014)
and the postmortem studies have been
highly informative in terms of revealing
whether the clinical improvementmatches
thedegreeof cell survival. Amajordiscrep-
ancy in this measure (i.e., clinical benefit
without cell survival) should raise ques-
tions as towhether the cell therapy is really
working through cell replacement or by
some nonspecific placebo effect.
Will Such a Therapy Ultimately
Be Competitive with the Other
Dopaminergic-Based Treatments
Already Available for PD?
There is no doubt that the ability to make
authentic dopaminergic nigral neurons
from stem cell sources will be realized,
although when this is considered to have
been achieved is clearly open to debate
(see above). However we already have
many therapies that work well on the
very aspects of PD being targeted by
these new therapies—this includes drug
(e.g., DuoDopa) and surgical (such as
DBS) therapies. As such, the question
arises as to whether any cell-based
therapy offers a primary advantage over
these other treatments in terms of effi-
cacy, cost, and ease of delivery, a ques-
tion that may ultimately only be answered
by a complex and large trial. Neverthe-
less, while the answer to this question is
unknown at this time, a few points are
worth making. First, the early use of a
dopamine cell therapy may dramatically
alter the natural history of PD by removingCell Stem Cell 15,the need to use oral dopaminergic agents
for years with all of their side-effects
and problems. These problems include
the development of on-off phenomena,
dyskinesias, and major behavioral prob-
lems in some patients taking dopamine
agonists. Second, many of the newer
medical and surgical therapies that were
thought to offer major advances in the
management of PD are now starting to
be seen to become less effective in the
long term as the disease progresses
(Rizzone et al., 2014). Third, the cost of
some of these newer therapies is very
high, and as such, cell therapies may be
cheaper, although this depends on who
ultimately owns, manufactures, and sells
this therapy.
Conclusion
In this short commentary I have tried to lay
out the roadmap for taking stem-cell-
derived dopaminergic neurons to the
clinic for treating PD. This involves under-
standing the history of the whole field of
cell-based therapies for PD and some
of the mistakes that have happened en
route. It requires a knowledge of what
the final product should look like and the
need to get there in a collaborative way
without being tempted to take short
cuts, because a premature clinical trial
could impact negatively on the whole
field of regenerative medicine. Finally,
the way one ultimately views the success
of this whole approach depends as much
on the success of competing therapies
and who in the end owns and sells the
cell-based product.
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